Intensity Therapeutics, Inc. Common stock (INTS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $10.17M
Last updated: Nov 17, 2026 at 11:04 AM ET
Intensity Therapeutics, Inc. Common stock (INTS) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Intensity Therapeutics, Inc. Common stock reported EPS of -$1.09, below the -$0.94 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
INTS's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
INTS Earnings Call
The latest INTS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 15 quarters below that had an estimate, INTS beat 4, missed 8 and matched 3. The widest gap in the table came in the quarter ended Dec 31, 2024, when EPS landed 431.82% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.09 | -$0.94 | -$1.12 - -$0.77 | -15.96% | Miss | N/A | 4 | 0 up, 3 down | Nov 5, 2026 |
| Jun 30, 2026 | -$1.11 | -$0.81 | -$0.93 - -$0.58 | -37.04% | Miss | N/A | 4 | 2 up, 1 down | Aug 11, 2026 |
| Mar 31, 2026 | -$0.96 | -$1.09 | -$1.19 - -$1.02 | +11.93% | Beat | N/A | 3 | 0 up, 0 down | May 7, 2026 |
| Dec 31, 2025 | -$1.21 | -$1.25 | -$1.45 - -$1.00 | +3.31% | Beat | N/A | 3 | 1 up, 0 down | Mar 27, 2026 |
| Sep 30, 2025 | -$1.50 | -$1.50 | -$1.50 - -$1.50 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Nov 6, 2025 |
| Jun 30, 2025 | -$0.13 | -$0.16 | N/A | +18.75% | Beat | N/A | 1 | 0 up, 0 down | Aug 7, 2025 |
| Mar 31, 2025 | -$5.50 | -$3.25 | -$3.25 - -$3.25 | -69.23% | Miss | N/A | 1 | 0 up, 0 down | May 13, 2025 |
| Dec 31, 2024 | -$1.17 | -$0.22 | N/A | -431.82% | Miss | N/A | N/A | 0 up, 0 down | Mar 13, 2025 |
| Sep 30, 2024 | -$6.25 | -$7.62 | -$9.25 - -$4.00 | +17.98% | Beat | N/A | 4 | 0 up, 2 down | Nov 13, 2024 |
| Jun 30, 2024 | -$9.00 | -$8.00 | -$8.50 - -$7.50 | -12.50% | Miss | N/A | 2 | 0 up, 0 down | Aug 8, 2024 |
| Mar 31, 2024 | -$8.50 | -$8.50 | N/A | 0.00% | In line | N/A | 1 | 0 up, 0 down | May 9, 2024 |
| Dec 31, 2023 | -$0.23 | -$0.18 | -$0.18 - -$0.18 | -28.56% | Miss | N/A | 1 | 0 up, 0 down | Mar 14, 2024 |
| Sep 30, 2023 | -$4.25 | -$2.25 | -$2.25 - -$2.25 | -88.89% | Miss | N/A | 1 | 0 up, 0 down | Nov 13, 2023 |
| Jun 30, 2023 | -$26.25 | -$10.00 | -$10.00 - -$10.00 | -162.50% | Miss | N/A | 1 | 0 up, 0 down | Aug 14, 2023 |
| Mar 31, 2023 | -$0.39 | -$0.39 | N/A | 0.00% | In line | N/A | N/A | N/A | Jun 30, 2023 |
| Sep 30, 2021 | -$0.24 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Oct 28, 2021 |
| Jun 30, 2021 | -$0.49 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 20, 2021 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$8.34, after -$24.92 the year before. It was -$31.85 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$8.34 | N/A |
| Dec 31, 2024 | -$24.92 | N/A |
| Dec 31, 2023 | -$31.85 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,200 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,225 | 7 | |
| 2026Q2 | Jun 30, 2026 | 5,410 | 7 |
2026Q3 Earnings Call
Opening remarks
Lewis Bender President and CEO Thank you, Wyatt, and thank you, everyone, for joining us this morning. It is my pleasure to provide the latest update of our company's progress in the INVINCIBLE-3 and INVINCIBLE-4 studies, our publications and presentation strategy, our business development activities, and our plans for the rest of 2026 into 2027. First, I will turn the call over to Joe Talamo, our CFO, to discuss our third quarter financial results. Joe?
Joseph Talamo CFO Thanks, Lou, and good morning. I'm pleased to join you today and to present a summary of our third quarter 2026 financial results. Our research and development expenses were $2.4 million for the third quarter of 2026, compared with $1.6 million for the same prior-year period, reflecting an increase of $876,000, or 56%. Clinical trial expenses for our Phase III INVINCIBLE-3 study were $1.5 million during the third quarter of 2026, compared with $1 million for the same prior-year period. In the current-year quarter, we resumed new patient enrollment activities in the INVINCIBLE-3 study at a limited number of U.S. sites after pausing new site activations and patient enrollment in March 2025 due to funding constraints. During this pause, we continued to treat and monitor patients previously enrolled in the study in cooperation with our clinical research organizations. We have prioritized commencing full patient enrollment and site activations once sufficient incremental funding is obtained. Our clinical trial expenses also included $104,000 for our Phase II INVINCIBLE-4 study, which also resumed patient enrollment and treatment in the third quarter of 2026. We expect the INVINCIBLE-4 study costs to increase in the coming quarters as we target completing enrollment in this study by the end of 2027. Lou will provide an operational update on both studies shortly. During the third quarter of 2026, we also initiated a new manufacturing batch of INT230-6, incurring $162,000 in higher manufacturing costs. We expect this batch will be completed in the first quarter of 2027 and will likely be sufficient to fully supply both ongoing clinical studies. Lastly, research and development employee compensation-related expenses were $184,000 higher during the current quarter due to an estimated bonus accrual in the current-year period, compared with no bonus accrual in the prior-year period. Turning now to G&A. General and administrative expenses were $1.3 million for the third quarter of 2026 and were unchanged compared with the same prior-year period. Within G&A, minor increases in employee compensation-related expenses and consulting expenses were offset by minor decreases in insurance costs during the third quarter of 2026 compared with the same prior-year period.
Frequently Asked Questions About INTS
Did INTS beat earnings estimates last quarter?
No. Intensity Therapeutics, Inc. Common stock reported EPS of -$1.09 for the quarter ended Sep 30, 2026, below the -$0.94 estimate by 15.96%.
What EPS do analysts expect from INTS next quarter?
The consensus EPS estimate for Intensity Therapeutics, Inc. Common stock for the quarter ending Dec 31, 2026 is -$0.77 from 7 analysts, with estimates from -$1.09 to -$0.21.
How often does INTS beat earnings estimates?
Intensity Therapeutics, Inc. Common stock beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -65.01%.
INTS pages: Overview, Earnings, Forecast, Financials, Competitors